PRNewswire: May 16, 2017 – PARIS, France – Micell Technologies announced today at the late-breaking trial session of EuroPCR— the official congress of the European Association of Percutaneous Cardiovascular Interventions—positive 12 month data from its DESSOLVE III clinical trial. The study met its…
PRNewswire: October 31, 2016 – DURHAM, NC, U.S.A. – Micell Technologies, Inc. (Micell) today announced that it presented five-year clinical safety and efficacy results from the DESSOLVE I and II trials of its MiStent sirolimus eluting absorbable polymer coronary stent system (MiStent® ). MiStent is…
